<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467270</url>
  </required_header>
  <id_info>
    <org_study_id>AP24534-14-203</org_study_id>
    <secondary_id>2014‐001617‐12</secondary_id>
    <secondary_id>15/LO/1192</secondary_id>
    <secondary_id>U1111-1238-0007</secondary_id>
    <nct_id>NCT02467270</nct_id>
  </id_info>
  <brief_title>Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses</brief_title>
  <acronym>OPTIC</acronym>
  <official_title>A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the efficacy of ponatinib administered in 3
      starting doses (45 milligram [mg], 30 mg, and 15 mg daily) in participants with CP-CML who
      are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as
      measured by less than or equal to (&lt;=) 1 percent (%) Breakpoint Cluster Region-Abelson
      Transcript Level using International Scale (BCR-ABL1IS) at 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is ponatinib. This study will characterize the safety and
      efficacy of ponatinib over a range of 3 starting doses.

      The study will enroll 276 participants in 3 cohorts and each cohort will have 92
      participants. All the participants will be randomized to receive once-daily oral
      administration of 1 of 3 starting doses of ponatinib:

        -  Cohort A: 45 mg ponatinib tablet

        -  Cohort B: 30 mg ponatinib tablet

        -  Cohort C: 15 mg ponatinib tablet

      The study is designed to consist of 2 periods: 24-cycle Main treatment period and optional
      treatment continuation period. Participants will be treated with their randomized dose of
      study drug in the Main Treatment Period until the occurrence of at least one of the
      following: absence of CHR by 3 months, absence of MCyR at 12 months, absence of &lt;=1%
      BCR-ABL1IS at 12 months, loss of &lt;=1% BCR-ABL1IS development of intolerance, or completion of
      all 24 cycles of treatment (whichever occurs first). Following completion of the 24-month
      main treatment period or following early withdrawal, participants may enter into an optional
      treatment continuation period.

      This multi-center trial will be conducted in the United States, United Kingdom, Republic of
      Korea, Spain, France, Taiwan, Australia, Canada, Italy, Chile, Japan, Germany, Argentina,
      Poland, Czech Republic, Denmark, Hong Kong, Portugal, Russia, Singapore, Switzerland, and
      Sweden. The overall time to participate in this study is approximately 60 months.
      Participants will make a final visit to the clinic approximately 30 days after the last dose
      of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with &lt;=1% BCR-ABL1IS at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Molecular Response (MMR) at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>MMR is defined as percentage of participants with major molecular response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Cytogenetic Response (MCyR) Rates by Month 12</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: greater than (&gt;) 0 to 35% Ph + metaphases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MMR</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Duration of MMR is defined as the interval between the first assessment at which the criteria for &lt;=1% MMR are met until the earliest date at which loss of &lt;=1% MMR occurs, or the criteria for progression are met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adjusted Incidence Rates for Arterial Occlusive Events (AOEs) and Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Percentage of participants with adjusted incidence rates who developed AOEs and VTEs will be categorized according to arterial occlusive events (Cardiac occlusive/thrombotic events, cerebral occlusive/thrombotic events and peripheral occlusive/thrombotic events) and venous thrombotic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CCyR at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Cytogenetic response is the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR is defined as 0% Ph+ metaphases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Molecular Response (MMR), Molecular Response 4 (MR4) and Molecular Response (MR4.5)</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>MR4 is defined as &lt;=0.01% BCR-ABL1IS. MR 4.5 is defined as &lt;=0.0032% BCR-ALB1IS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Molecular Response 1 (MR1) at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>MR1 is defined as percentage of participants achieving a ratio of &lt;=10% Breakpoint Cluster Region-abelson (BCR-ABL1) transcripts on the international scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete hematologic Response (CHR) at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>CHR is defined as achieving all of the following measurements: white blood cells (WBC) &lt;= institutional upper limit of normal (ULN), platelets less than (&lt;) 450,000 per cubic millimeter (/mm^3), no blasts or promyelocytes in peripheral blood, &lt;5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt;5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with AEs Leading to Discontinuation and Dose Reduction</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Dose Interruptions</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) of &lt;=1% BCR-ABL1 IS</measure>
    <time_frame>From the first assessment at which the criteria for &lt;= 1% BCR-ABL1IS are met until the earliest date at which loss of &lt;= 1% BCR-ABL1IS occurs, or the criteria for progression are met (up to 6.3 years)</time_frame>
    <description>Duration of &lt;=1% BCR-ABL1IS is defined as the interval between the first assessment at which the criteria for &lt;=1% BCR-ABL1IS are met until the earliest date at which loss of &lt;=1% BCR-ABL1IS occurs, or the criteria for progression (progression to accelerated phase [AP] or blast phase [BP] of CML) are met. Loss of &lt;=1% BCR-ABL1IS is an increase to &gt;1% of BCR-ABL1IS. Progression to AP is defined as: greater than or equal to (&gt;=) 15% and &lt;30% blasts in peripheral blood or bone marrow or &gt;=20% basophils in peripheral blood or bone marrow or &gt;=30% blasts + promyelocytes in peripheral blood or bone marrow (but &lt;30% blasts) or &lt;100*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: &gt;=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR for MMR</measure>
    <time_frame>From the first assessment at which the criteria for MMR are met until the earliest date at which loss of MMR occurs, or the criteria for progression are met (up to 6.3 years)</time_frame>
    <description>Duration of MMR is defined as the interval between the first assessment at which the criteria for MMR are met until the earliest date at which loss of MMR occurs, or the criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at the last date at which the criteria for MMR are met. Loss of MMR is an increase to &gt;1% of BCR-ABL1IS. Progression to AP is defined as: &gt;= 15% and &lt;30% blasts in peripheral blood or bone marrow or &gt;=20% basophils in peripheral blood or bone marrow or &gt;=30% blasts + promyelocytes in peripheral blood or bone marrow (but &lt;30% blasts) or &lt;100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: &gt;=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR in Responders</measure>
    <time_frame>Baseline up to 6.3 years</time_frame>
    <description>Responders are defined as those participants who meet all of the following: are randomized and treated, respond at 12 months after the initiation of study treatment, and undergo baseline polymerase chain reaction (PCR) assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Baseline up to 6.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Progression to AP or BP CML</measure>
    <time_frame>From first dose date of study treatment until death due to any cause, censored at the last response assessment (up to 6.3 years)</time_frame>
    <description>Progression to AP is defined as: &gt;=15% and &lt;30% blasts in peripheral blood or bone marrow or &gt;=20% basophils in peripheral blood or bone marrow or &gt;=30% blasts + promyelocytes in peripheral blood or bone marrow (but &lt;30% blasts) or &lt;100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: &gt;=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From first dose date of study treatment until first date at which criteria for progression are met, or death due to any cause, censored at the last response assessment (up to 6.3 years)</time_frame>
    <description>PFS is defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression are met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP is defined as: &gt;=15% and &lt;30% blasts in peripheral blood or bone marrow or &gt;=20% basophils in peripheral blood or bone marrow or &gt;=30% blasts + promyelocytes in peripheral blood or bone marrow (but &lt;30% blasts) or &lt;100*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: &gt;=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first dose date of study treatment until death due to any cause, censored at the last contact date when the participant was alive (up to 6.3 years)</time_frame>
    <description>OS is defined as the interval between the first does of study treatment and death due to any cause, censored at the last contact date when the participant was alive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Myeloid Leukemia, Chronic, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ponatinib 45 mg once daily starting dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ponatinib 30 mg once daily starting dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ponatinib 15 mg once daily starting dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 45 mg</intervention_name>
    <description>45 mg tablet, taken orally once daily.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 30 mg</intervention_name>
    <description>30 mg tablet, taken orally once daily.</description>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 15 mg</intervention_name>
    <description>15 mg tablet, taken orally once daily.</description>
    <arm_group_label>Cohort C</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have CP-CML and have received at least two prior TKI therapies and have demonstrated
             resistance to treatment OR have documented history of presence of T315I mutation after
             receiving any number of prior TKI.

             o The diagnosis of chronic myeloid leukemia (CML) will be made using standard
             hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the
             following: i &lt;15% blasts in bone marrow ii &lt;30% blasts plus promyelocytes in bone
             marrow iii &lt;20% basophils in peripheral blood. iv &gt;= 100*10^9/liter (L) platelets
             (&gt;=100,000/mm^3). v No evidence of extramedullary disease except hepatosplenomegaly vi
             No prior diagnosis of AP-CML, and BP-CML

             o Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by presence
             of the t(9;22) Philadelphia chromosome.

             i Variant translocations are only allowed provided they meet inclusion criterion 1d.

             o Resistance to prior TKI therapy is defined as follows (participants must meet at
             least 1 criterion): i Three months after the initiation of prior TKI therapy: No
             cytogenetic response (&gt;95% Ph+) or failure to achieve CHR or new mutation ii Six
             months after the initiation of prior TKI therapy: BCR-ABL1IS &gt;10% and/or Ph+ &gt;65% or
             new mutation iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS
             &gt;10% and/or Ph+ &gt;35% or new mutation iv At any time after the initiation of prior TKI
             therapy, the development of a new BCR-ABL1 kinase domain mutation(s) v At any time
             after the initiation of prior TKI therapy, the development of new clonal evolution vi
             At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or
             the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS
             transcript level of &gt;=1% or new mutation

             o &gt;1% of BCR-ABL1IS as shown by real-time polymerase chain reaction

          2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          3. Have adequate renal function as defined by the following criterion:

               -  Serum creatinine &lt;=1.5*ULN for institution

               -  Estimated creatinine clearance &gt;=30 milliliter per minute (mL/min)
                  (Cockcroft-Gault formula)

          4. Have adequate hepatic function as defined by the following criteria:

               -  Total serum bilirubin &lt;=1.5*ULN, unless due to Gilbert's syndrome

               -  Alanine transaminase (ALT) &lt;=2.5*ULN, or &lt;=5*ULN if leukemic infiltration of the
                  liver is present

               -  Aspartate transaminase (AST) &lt;=2.5*ULN, or &lt;=5*ULN if leukemic infiltration of
                  the liver is present

          5. Have normal pancreatic status as defined by the following criterion:

             o Serum lipase and amylase &lt;=1.5*ULN

          6. Have normal QT interval corrected (Frederica) (QTcF) interval on screening
             electrocardiogram (ECG) evaluation, defined as QTcF of &lt;=450 milliseconds (ms) in
             males or &lt;=470 ms in females.

          7. Have a negative pregnancy test documented prior to enrollment (for females of
             childbearing potential).

          8. Agree to use a highly effective form of contraception with sexual partners from
             randomization through at least 4 months after the end of treatment (for female and
             male participants who are fertile).

          9. Provide written informed consent.

         10. Be willing and able to comply with scheduled visits and study procedures.

         11. Have recovered from toxicities related to prior anticancer therapy to National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade
             &lt;=1.

        Exclusion Criteria:

          1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives
             of the agent, whichever is longer, prior to receiving study drug.

          2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other
             cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior
             to receiving the first dose of ponatinib, or have not recovered (&gt;grade 1 by NCI
             CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered.

          3. Have undergone autologous or allogeneic stem cell transplant &lt;60 days prior to
             receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host
             disease (GVHD) or GVHD requiring immunosuppressive therapy.

          4. Are being considered for hematopoietic stem cell transplant (HSCT) within 6-12 months
             of enrollment (note: ponatinib is not to be used as a bridge to HSCT in this trial).

          5. Are taking medications with a known risk of Torsades de Pointes.

          6. Have previously been treated with ponatinib.

          7. Have active CNS disease as evidenced by cytology or pathology; in the absence of
             clinical CNS disease, lumbar puncture is not required. History itself of CNS
             involvement is not exclusionary if CNS has been cleared with a documented negative
             lumbar puncture.

          8. Have clinically significant, uncontrolled, or active cardiovascular disease,
             specifically including, but not restricted to:

               -  Any history of myocardial infarction (MI), unstable angina, cerebrovascular
                  accident, or Transient Ischemic Attack (TIA)

               -  Any history of peripheral vascular infarction, including visceral infarction

               -  Any revascularization procedure, including the placement of a stent

               -  Congestive heart failure (CHF) (New York Heart Association [NYHA] class III or
                  IV) within 6 months prior to enrollment, or left ventricular ejection fraction
                  (LVEF) less than lower limit of normal, per local institutional standards, within
                  6 months prior to enrollment

               -  History of clinically significant (as determined by the treating physician)
                  atrial arrhythmia or any history of ventricular arrhythmia

               -  Venous thromboembolism, including deep venous thrombosis or pulmonary embolism,
                  within 6 months prior to enrollment

          9. Have uncontrolled hypertension (that is, &gt;150 and &gt;90 for systolic blood pressure
             (SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension
             should be under treatment at study entry to ensure blood pressure control. Those
             requiring 3 or more antihypertensive medications should be discussed with the medical
             monitor.

         10. Have poorly controlled diabetes defined as HbA1c values of &gt;7.5%. Participants with
             preexisting, well-controlled diabetes are not excluded.

         11. Have a significant bleeding disorder unrelated to CML.

         12. Have a history of alcohol abuse.

         13. Have a history of either acute pancreatitis within 1 year of study enrollment or of
             chronic pancreatitis.

         14. Have malabsorption syndrome or other gastrointestinal illness that could affect oral
             absorption of study drug.

         15. Have a history of another malignancy, other than cervical cancer in situ or basal cell
             or squamous cell carcinoma of the skin; the exception is if participants have been
             disease-free for at least 5 years, and are deemed by the investigator to be at low
             risk for recurrence of that malignancy.

         16. Are pregnant or lactating.

         17. Have undergone major surgery (with the exception of minor surgical procedures, such as
             catheter placement or BM biopsy) within 14 days prior to first dose of ponatinib.

         18. Have an active infection which requires intravenous antibiotics.

         19. Have a known history of human immunodeficiency virus infection; testing is not
             required in the absence of prior documentation or known history.

         20. Have any condition or illness that, in the opinion of the investigator, would
             compromise participant safety or interfere with the evaluation of the drug.

         21. Have hypersensitivity to the ponatinib active substance or to any of its inactive
             ingredients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood &amp; Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical School</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute Main Campus</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundaleu</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1114AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudo Jose Maria Ramos Mejia</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano La Plata</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AXI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Salvador</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <zip>7500922</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas Vina del Mar</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2540364</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ustav Hematologie a Krevni Transfuze Praha</name>
      <address>
        <city>Prague</city>
        <state>Praha</state>
        <zip>12820</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <state>\Aarhus</state>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer - Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nancy Hopital de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Lorraine</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Midi-pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Lille</name>
      <address>
        <city>Lille cedex</city>
        <state>NORD Pas-de-calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <state>PAYS DE LA Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <state>PAYS DE LA Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers Cedex</city>
        <state>Poitou-charentes</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice Hopital l'Archet</name>
      <address>
        <city>Nice Cedex 3</city>
        <state>Provence Alpes COTE D'azur</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-wuerttemberg</state>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <state>Pesaro E Urbino</state>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale di Pescara Ospedale Civile Dello Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapienza Universita Di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUI - Ospedale Policlinico &quot;Giambattista Rossi&quot; di Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>6591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Lisboa Francisco Gentil</name>
      <address>
        <city>Lisboa</city>
        <zip>1090-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Sao Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-na-Donu</city>
        <state>Rostov</state>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Moscow Clinical Scientific Center DZM</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Academy of Medical Science</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGU Russian Scientific Research Institute of Hematology and Transfusiology</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov Federal North-West Medical Research Centre of Department of Health of Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>355018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Doctor Nergrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>LAS Palmas</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Japan</country>
    <country>Norway</country>
  </removed_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203469s009lbl.pdf</url>
    <description>Iclusig® (ponatinib) US Prescribing Information</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Phase Chronic Myeloid Leukemia</keyword>
  <keyword>Molecular Response</keyword>
  <keyword>CML</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>CP-CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

